

FIG. 1




FIG. 2




FIG. 3




FIG. 4




FIG. 6




FIG. 5

INHIBITION OF ANTI-MUC1 ANTIBODY POSITIVE
PATIENT SAMPLES WITH MUC1-DERIVED PEPTIDES
UNTREATED SAMPLES (FREE ANTIBODIES)




FIG. 7A-1




FIG. 7A-2

5/12

Patient MK




FIG. 7A-3

Patient MJG




FIG. 7A-4

6/12

Patient AK




FIG. 7A-5

Patient RAN




FIG. 7A-6

7/12

Patient KMC




FIG. 7A-7

Assay Controls






FIG. 7A-8

CONTROLS		Original Value [U/ml]	31-mer	DTRPAP	Peptide			
Standard	100 U/ml				APGSTA	TAPPAH	AHGVTS	TSAPDT
Standard	200 U/ml	100	25.9	23.4	3.9	3.3	7.6	4.7
		200	21.0	15.0	-1.7	-8.9	-5.3	-11.4



AR20.5 Control



COMMENT:
Only the 31-mer MUC1 peptide (same as used for coating and the DTRPAP peptide inhibit the binding of AR20.5. These results are consistent with previous studies indicating minimum MUC1 epitope recognized by AR20.5 is DTRPA. Inhibition should be at least 10% to be considered as pos.

FIG. 7A-9

9/12

INHIBITION OF ANTI-MUC1 ANTIBODY POSITIVE
PATIENT SAMPLES WITH MUC1-DERIVED PEPTIDES
TREATED SAMPLES (FREE AND MUC1-COMPLEXED SAMPLES)




FIG. 7B-1




FIG. 7B-2

10/12




FIG. 7B-3




FIG. 7B-4

11/12

Patient AK




FIG. 7B-5

Patient RAN




FIG. 7B-6

Patient KMC




FIG. 7B-7

Assay Controls




FIG. 7B-8